Study guide
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns
Key Takeaways Explain This Topic AI
Lung cancer, breast cancer, and melanoma are the most common sources of brain metastases, which preferentially lodge at the gray-white matter junction.
Leptomeningeal spread through the CSF can seed the entire neuraxis, which is why craniospinal irradiation for medulloblastoma treats the brain and spinal subarachnoid space down to the thecal sac.
The optic chiasm, brainstem, cochlea, lens, hippocampus, and spinal cord are the key dose-limiting structures in CNS radiotherapy.
Stereotactic radiosurgery delivers ablative, highly conformal dose to a limited number of brain metastases, while whole-brain radiotherapy treats diffuse or numerous lesions.
Rigid mask or frame immobilization plus daily image guidance are essential given the small margins used in cranial and spinal treatment.
Last updated: July 2026
Overview and Relevant Anatomy
The central nervous system (CNS) presents unique radiotherapy challenges because of its complex anatomy, densely packed radiosensitive substructures, and the influence of the blood-brain barrier on tumor biology and drug delivery. The brain is organized into the cerebrum (frontal, parietal, temporal, and occipital lobes), the cerebellum, the brainstem (midbrain, pons, and medulla oblongata), and the diencephalon (thalamus, hypothalamus, and pituitary gland). Three meningeal layers — dura mater, arachnoid mater, and pia mater — envelop the brain and spinal cord, and cerebrospinal fluid (CSF) circulates through the ventricular system and subarachnoid space, cushioning neural tissue and providing a pathway for tumor cell dissemination.
Primary CNS tumors arise from several cell lineages: glial cells produce astrocytomas, oligodendrogliomas, and glioblastoma multiforme (GBM); the meninges give rise to meningiomas; embryonal precursor cells in the cerebellum produce medulloblastoma, the most common malignant pediatric brain tumor; ependymal cells lining the ventricles produce ependymoma; and the sellar/pineal region produces pituitary adenomas, craniopharyngiomas, and germ cell tumors. GBM (WHO grade 4, typically IDH-wildtype) is the most common malignant primary brain tumor in adults. It infiltrates diffusely along white matter tracts, which is why gross total resection rarely achieves cure and postoperative radiotherapy with concurrent temozolomide is standard of care.
The spinal cord extends from the foramen magnum to roughly the L1-L2 vertebral level in adults, tapering into the conus medullaris and continuing as the cauda equina nerve roots. Intramedullary tumors (ependymoma, astrocytoma) arise within the cord itself, while extramedullary tumors (meningioma, schwannoma) and epidural metastatic disease compress the cord from outside. Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency; delayed treatment risks permanent paraplegia, so same-day or next-day simulation and treatment initiation is often required.
- Tumor Type Cell Origin Typical Location Key Feature
- Glioblastoma (GBM) Astrocytic glia Cerebral hemispheres Diffuse infiltration, necrotic core, poor prognosis
- Meningioma Arachnoid cap cells Dural surface, falx, convexity Usually benign/slow-growing, extra-axial
Medulloblastoma Cerebellar embryonal cells Posterior fossa (4th ventricle) High CSF dissemination risk; treated with craniospinal irradiation
- Ependymoma Ependymal lining cells Ventricles, spinal cord Can seed CSF; posterior fossa most common site
- Pituitary adenoma Anterior pituitary cells Sella turcica May compress optic chiasm, causes hormonal syndromes
Metastatic Patterns and CSF Spread
Brain metastases are dramatically more common than primary brain tumors, developing in an estimated 20-40% of adult cancer patients during their disease course. Lung cancer is the most frequent source of brain metastases, followed by breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Melanoma carries the highest per-lesion propensity to spread to the brain despite lung and breast cancers producing more absolute cases because those primaries are simply more prevalent overall. Hematogenous spread through the arterial circulation explains why metastases preferentially lodge at the gray-white matter junction: small-caliber vessels narrow abruptly at this boundary, trapping tumor emboli that then proliferate.
Leptomeningeal spread, also called carcinomatous meningitis, occurs when malignant cells seed the CSF and coat the pia-arachnoid surfaces of the brain and spinal cord. It is diagnosed through CSF cytology and MRI findings of linear or nodular leptomeningeal enhancement, and it is seen most often with breast cancer, lung cancer, melanoma, and hematologic malignancies such as leukemia and lymphoma. Because CSF bathes the entire neuraxis, malignant cells can travel freely from the ventricles down to the lumbar thecal sac, producing so-called drop metastases. This phenomenon is the direct rationale for craniospinal irradiation (CSI) in medulloblastoma and other tumors prone to CSF dissemination: CSI treats the whole brain and the entire spinal subarachnoid space, extending inferiorly to cover the thecal sac (typically to the S2-S3 level, confirmed on MRI), because imaging alone cannot reliably exclude microscopic seeding anywhere along that pathway.
Critical Organs at Risk and Therapist Considerations
Several radiosensitive structures dictate planning constraints and daily setup priorities:
Optic chiasm and optic nerves: risk of radiation-induced optic neuropathy; conventional point-dose constraints are typically kept below roughly 54-55 Gy.
Brainstem: tolerance is comparatively low, and overdose can cause severe, potentially fatal toxicity, so brainstem point-dose limits are enforced strictly, especially in posterior fossa and skull-base plans.
Cochlea: sensorineural hearing loss is a long-term risk, particularly relevant in posterior fossa treatment and craniospinal irradiation for medulloblastoma.
Lens: cataract formation is dose-dependent; lens dose is minimized whenever fields pass near the orbits.
Hippocampus: implicated in memory and learning; hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) has been shown to reduce neurocognitive decline in appropriately selected patients.
Spinal cord: myelopathy risk is dose- and volume-dependent; cord constraints become especially critical in re-irradiation scenarios.
Treatment approach depends on disease extent and biology. Whole-brain radiotherapy (WBRT) treats multiple or diffuse metastases; stereotactic radiosurgery (SRS) delivers a highly conformal, ablative dose in one to five fractions for a limited number (roughly one to ten) of metastases, sparing normal brain through sharp dose fall-off; craniospinal irradiation covers the full neuraxis for medulloblastoma or other CSF-disseminating tumors; and fractionated conformal/IMRT plans for gliomas typically encompass the enhancing tumor plus surrounding T2/FLAIR signal abnormality with an additional margin to account for infiltrative disease.
From the therapist's perspective, rigid immobilization is paramount. Thermoplastic masks (often three- or five-point fixation) secure the head for fractionated treatment, while SRS frequently uses more rigid mask systems or stereotactic frames because sub-millimeter accuracy is required at the small treatment margins used. Daily image guidance -- cone-beam CT or optical surface tracking -- verifies position given the minimal planning target volume margins. For craniospinal irradiation, therapists must precisely match adjacent cranial and spinal fields, often using junction shifts partway through treatment, to avoid a cold or hot junction spot where fields abut along the spine.